Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology

Advanced search

Initiation and intensification of insulin therapy in patients with type 2 diabetes mellitus: a budget impact analysis

https://doi.org/10.17749/2070-4909.2017.10.3.003-010

Full Text:

Abstract

To date, several options for starting and intensifying insulin therapy in patients with type 2 diabetes mellitus (T2DM) have been proposed. Meta-analyzes of the recent results shows that, with adequate use, all these regimens have the similar efficacy and safety; therefore, when choosing a therapeutic approach, the patient’s requirements and preferences become highly significant. The aim of this study was to assess how changes in the current practice of insulin therapy in patients with T2DM can impact the federal healthcare budget. Materials and Methods. Based on the results of the DURABLE clinical trial, we created a “decision tree” model that allowed us to calculate the costs of 48-week insulin therapy in 1000 T2DM patients who had never received insulin before that trial. The cases selected for modeling included patients on one of two starting regimens – basal insulin (glargine) or a ready-made mixture (biphasic lispro 25). After 24 weeks, upon achieving or not achieving the target HbA1c values, a decision was made whether to intensify the therapy by using the basal bolus therapy (glargine and lispro) or the ready-made mixtures (biphasic 25 or 50 lispro). The weighted average price of 1 IU insulin (according to public procurement data) was used for calculations. Results. Within the current practice of prescribing ready-made mixtures at the start and the intensification rate of 20%, the annual cost of purchasing insulin for the model population of 1,000 patients was 22.5 million rubles. If the use of ready-made mixtures increased to 35% at initiation and to 50% with intensification, the costs would be reduced by by 1.9 million rubles. In the cases when only basal insulin was prescribed for the start, the annual costs amounted to 23.8 million rubles (if only 20% of patients received a ready-made mixture with intensification) and to 22.8 million (if 50% of patients received a ready-made mixture with intensification). Conclusion. As a result of this analysis, an increase in the number of patients who use a ready-made mixture for the initiation or intensification of insulin therapy can lead to reducing the budget costs for purchasing insulin analogues for patients with type 2 diabetes mellitus.

About the Authors

E. V. Biryukova
A. I. Yevdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of the Russian Federation
Russian Federation

Biryukova Elena Valer’evna – MD, Professor, the Department of endocrinology and diabetology at the Moscow State University of Medicine and Dentistry.

Address: ul. Delegatskaya, 20-1, Moscow, 127473



V. I. Ignat’eva
The Russian Presidential Academy of National Economy and Public Administration

Ignatyeva Viktoria Igorevna – Researcher at the Center for Health Technology Assessment

Address: Vernadskogo prospect, 82, Moscow, Russia, 119571.



References

1. Standards of medical care in diabetes – 2017. Diabetes Care. 2017; 40 (1): 1-142.

2. Giugliano D., Sieradzki J., Stefanski A., Gentilella R. Personalized intensification of insulin therapy in type 2 diabetes – does a basal-bolus regimen suit all patients? Curr Med Res Opin. 2016; 32 (8): 1425-34.

3. Turner H. E., Matthews D. R. The use of fixed-mixture insulins in clinical practice. Eur J Clin Pharmacol. 2000; 56 (1): 19-25.

4. Maiorino M. I., Bellastella G., Esposito K., Giugliano D. Premixed insulin regimens in type 2 diabetes. Pros. Endocrine. 2017; 55 (1): 45-50.

5. Chazova T. Russkii meditsinskii zhurnal (in Russian). 2003; 11 (27): 15-20.

6. Kalashnikova M. F., Belousov D. Yu., Suntsov Yu. I., Kantemirova M. A., Dedov I. I. Sakharnyi diabet (in Russian). 2015; 18 (2): 32-46.

7. Algorithms of specialized medical care for patients with diabetes mellitus. Ed. I. I. Dedova, M. V. Shestakova, A. Yu. Mayorova. The 8th issue [Algoritmy spetsializirovannoi meditsinskoi pomoshchi bol’nym sakharnym diabetom. Pod red. I. I. Dedova, M. V. Shestakovoi, A.Yu. Maiorova. 8-i vypusk (in Russian)]. Moscow. 2017; 112 s.

8. Buse J. B., Wolffenbuttel B. H., Herman W. H., Shemonsky N. K., Jiang H. H., Fahrbach J. L., Scism-Bacon J. L., Martin S. A. DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes. Diabetes Care. 2009; 32 (6): 1007-13.

9. Miser W. F., Arakaki R., Jiang H., Scism-Bacon J., Anderson P. W., Fahrbach J. L. Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial. Clin Ther. 2010; 32 (5): 896-908.

10. Dedov I. I., Omel’yanovskii V. V., Shestakova M. V., Avksent’eva M. V., Ignat’eva V. I. Sakharnyi diabet (in Russian). 2016; 19 (1): 30-43.

11. Type 2 diabetes in adults: management (NG28). NICE guideline. URL: nice.org.uk/guidance/ng28. Accessed: 25.05.2017.

12. Swinnen S. G., Simon A. C., Holleman F., Hoekstra J. B., Devries J. H. Insulin detemir versus insulin glargine for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2011.10.1002/14651858. CD006383.pub2 № 7. C. CD006383.

13. Lasserson D. S., Glasziou P., Perera R., Holman R. R., Farmer A. J. Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses. Diabetologia. 2009; 52 (10): 1990-2000.

14. Rys P., Wojciechowski P., Siejka S., Malecki P., Hak L., Malecki M. T. A comparison of biphasic insulin aspart and insulin glargine administered with oral antidiabetic drugs in type 2 diabetes mellitus – a systematic review and meta-analysis. Int J Clin Pract. 2014; 68 (3): 304-13.

15. Wang C., Mamza J., Idris I. Biphasic vs basal bolus insulin regimen in Type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabet Med. 2015; 32 (5): 585-94.

16. Giugliano D., Chiodini P., Maiorino M. I., Bellastella G., Esposito K. Intensification of insulin therapy with basal-bolus or premixed insulin regimens in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Endocrine. 2016; 51 (3): 417-28

17. Giugliano D., Maiorino M. I., Bellastella G., Chiodini P., Ceriello A., Esposito K. Efficacy of insulin analogs in achieving the hemoglobin A1c target of<7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes Care. 2011; 34 (2): 510-7.


For citation:


Biryukova E.V., Ignat’eva V.I. Initiation and intensification of insulin therapy in patients with type 2 diabetes mellitus: a budget impact analysis. FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology. 2017;10(3):3-10. (In Russ.) https://doi.org/10.17749/2070-4909.2017.10.3.003-010

Views: 152


ISSN 2070-4909 (Print)
ISSN 2070-4933 (Online)